https://www.nytimes.com/2021/02/19/opinion/covid-s
Post# of 72440
For those of you fascinated by the epidemiology and origins of contagions, I recommend this NYTimes Opinion piece written by David Quammen. Quammen is an excellent writer/scientist. I first read his work a decade ago when he published Spillover. I strongly recommend this book. In fact, I’ve been recommending it to friends and family since I first read it and have done so dozens of times during the current pandemic. I am sure many in this community have read it. If you have you may agree with me that Spillover and Quammen’s other books represent a chicken or egg model. As in; Read it, becomes a biotech investor or became a biotech investor, read it. It an essential text for those who wish to know why.
On an Innovation Pharmaceuticals note; for those who might argue the COVID-19 opportunity is past (it isn’t), and IPIX has missed the bus (it hasn’t), there will be other buses. Brilacidin has pan-Corona potential. Modeled after nature’s Host Defense Proteins (HDPs), Brilacidin, destroys virus (and bacteria, and fungal pathogens), by rupturing their cell membrane. Brilacidin will play a vital role as humanities first line of defense, first-in-class cure for existing and novel (emerging), illnesses for decades to come, in the form of multiple indications. Know what you own. Know it potential value.